CHMP recommendation adds to Teva’s financial turmoil

Eric Palmer

Regulators in Europe refused to give a favorable review to laquinimod, a potential successor treatment to Teva's multiple sclerosis drug Copaxone, which faces generic competition in May.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS